Diana F. Hausman - 09 May 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Reporting relationship: Chief Medical Officer
Issuer ticker: ZNTL
Reported as of: 09 May 2024
Net transaction value: -$42,353
SEC form: 4
Accepted by SEC: 09 May 2024, 19:46:59 UTC
Prior SEC filing: 05 Feb 2024
Next SEC filing: 13 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Andrea Paul, attorney-in-fact for Diana Hausman

Filing notes and source

Key filing fact

Diana F. Hausman filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 09 May 2024.

Key facts

This page summarizes Diana F. Hausman's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 May 2024, 19:46.

Change

Previous filing in this sequence was filed on 05 Feb 2024.
Current net transaction value: -$42,353.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZNTL transaction

Common Stock

Sale

Transaction value: $42,353
Shares: -3,356
Change %: -0.89%
Price: $12.62
Shares after: 373,876
Date: 09 May 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

SEC remarks

Exhibit 24 - Power of Attorney